Prognostic assessment in COPD without lung function: the B-AE-D indices

Lucas Boeck, Joan B. Soriano, Marjolein Brusse-Keizer, Francesco Biasi, Konstantinos Kostikas, Wim Boersma, Branislava Milenkovic, Renaud Louis, Alicia Lacoma, Remco Djamin, Joachim Aerts, Antoni Torres, Gernot Rohde, Tobias Welte, Pablo Martinez-Camblor, Janko Rakic, Andreas Scherr, Michael Koller, Jacobus Adrianus Maria van der Palen, Jose M. Gomez Marin & 10 others Inmaculada Alfageme, Pere Almagro, Ciro Casanova, Christobal Esteban, Juan J. Soler-Cataluna, Juan P. de Torres, Marc Miravitlles, Bartolome R. Celli, Michael Tamm, Daiana Stolz

Research output: Contribution to journalArticleAcademic

18 Citations (Scopus)

Abstract

Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function. The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988). Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C. It was observed that B-AE-D and B-AE-D-C were at least as good as BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity), ADO (age, dyspnoea, airflow obstruction) and DOSE (dyspnoea, obstruction, smoking, exacerbation) indices for predicting 2-year all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 0.63, respectively; Hosmer–Lemeshow test all p>0.05). Both indices were COPD specific (c-statistic for predicting COPD-related 2-year mortality: 0.87 and 0.89, respectively). External validation of B-AE-D was performed in COCOMICS and COMIC (c-statistic for 1-year all-cause mortality: 0.68 and 0.74; c-statistic for 2-year all-cause mortality: 0.65 and 0.67; Hosmer–Lemeshow test all p>0.05). The B-AE-D index, plus copeptin if available, allows a simple and accurate assessment of COPD-related risk
Original languageEnglish
Pages (from-to)1601-1605
JournalEuropean respiratory journal
Volume47
Issue number6
DOIs
Publication statusPublished - 2016

Fingerprint

Chronic Obstructive Pulmonary Disease
Lung
Dyspnea
Mortality
Dilatation and Curettage
Body Mass Index
Biomedical Research
Smoking
Exercise

Keywords

  • IR-101435
  • METIS-318027

Cite this

Boeck, L., Soriano, J. B., Brusse-Keizer, M., Biasi, F., Kostikas, K., Boersma, W., ... Stolz, D. (2016). Prognostic assessment in COPD without lung function: the B-AE-D indices. European respiratory journal, 47(6), 1601-1605. https://doi.org/10.1183/13993003.01485-2015
Boeck, Lucas ; Soriano, Joan B. ; Brusse-Keizer, Marjolein ; Biasi, Francesco ; Kostikas, Konstantinos ; Boersma, Wim ; Milenkovic, Branislava ; Louis, Renaud ; Lacoma, Alicia ; Djamin, Remco ; Aerts, Joachim ; Torres, Antoni ; Rohde, Gernot ; Welte, Tobias ; Martinez-Camblor, Pablo ; Rakic, Janko ; Scherr, Andreas ; Koller, Michael ; van der Palen, Jacobus Adrianus Maria ; Gomez Marin, Jose M. ; Alfageme, Inmaculada ; Almagro, Pere ; Casanova, Ciro ; Esteban, Christobal ; Soler-Cataluna, Juan J. ; de Torres, Juan P. ; Miravitlles, Marc ; Celli, Bartolome R. ; Tamm, Michael ; Stolz, Daiana. / Prognostic assessment in COPD without lung function: the B-AE-D indices. In: European respiratory journal. 2016 ; Vol. 47, No. 6. pp. 1601-1605.
@article{baadfef1c7e146f09e8492f073a962ac,
title = "Prognostic assessment in COPD without lung function: the B-AE-D indices",
abstract = "Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function. The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988). Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C. It was observed that B-AE-D and B-AE-D-C were at least as good as BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity), ADO (age, dyspnoea, airflow obstruction) and DOSE (dyspnoea, obstruction, smoking, exacerbation) indices for predicting 2-year all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 0.63, respectively; Hosmer–Lemeshow test all p>0.05). Both indices were COPD specific (c-statistic for predicting COPD-related 2-year mortality: 0.87 and 0.89, respectively). External validation of B-AE-D was performed in COCOMICS and COMIC (c-statistic for 1-year all-cause mortality: 0.68 and 0.74; c-statistic for 2-year all-cause mortality: 0.65 and 0.67; Hosmer–Lemeshow test all p>0.05). The B-AE-D index, plus copeptin if available, allows a simple and accurate assessment of COPD-related risk",
keywords = "IR-101435, METIS-318027",
author = "Lucas Boeck and Soriano, {Joan B.} and Marjolein Brusse-Keizer and Francesco Biasi and Konstantinos Kostikas and Wim Boersma and Branislava Milenkovic and Renaud Louis and Alicia Lacoma and Remco Djamin and Joachim Aerts and Antoni Torres and Gernot Rohde and Tobias Welte and Pablo Martinez-Camblor and Janko Rakic and Andreas Scherr and Michael Koller and {van der Palen}, {Jacobus Adrianus Maria} and {Gomez Marin}, {Jose M.} and Inmaculada Alfageme and Pere Almagro and Ciro Casanova and Christobal Esteban and Soler-Cataluna, {Juan J.} and {de Torres}, {Juan P.} and Marc Miravitlles and Celli, {Bartolome R.} and Michael Tamm and Daiana Stolz",
year = "2016",
doi = "10.1183/13993003.01485-2015",
language = "English",
volume = "47",
pages = "1601--1605",
journal = "European respiratory journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

Boeck, L, Soriano, JB, Brusse-Keizer, M, Biasi, F, Kostikas, K, Boersma, W, Milenkovic, B, Louis, R, Lacoma, A, Djamin, R, Aerts, J, Torres, A, Rohde, G, Welte, T, Martinez-Camblor, P, Rakic, J, Scherr, A, Koller, M, van der Palen, JAM, Gomez Marin, JM, Alfageme, I, Almagro, P, Casanova, C, Esteban, C, Soler-Cataluna, JJ, de Torres, JP, Miravitlles, M, Celli, BR, Tamm, M & Stolz, D 2016, 'Prognostic assessment in COPD without lung function: the B-AE-D indices' European respiratory journal, vol. 47, no. 6, pp. 1601-1605. https://doi.org/10.1183/13993003.01485-2015

Prognostic assessment in COPD without lung function: the B-AE-D indices. / Boeck, Lucas; Soriano, Joan B.; Brusse-Keizer, Marjolein; Biasi, Francesco; Kostikas, Konstantinos; Boersma, Wim; Milenkovic, Branislava; Louis, Renaud; Lacoma, Alicia; Djamin, Remco; Aerts, Joachim; Torres, Antoni; Rohde, Gernot; Welte, Tobias; Martinez-Camblor, Pablo; Rakic, Janko; Scherr, Andreas; Koller, Michael; van der Palen, Jacobus Adrianus Maria; Gomez Marin, Jose M.; Alfageme, Inmaculada; Almagro, Pere; Casanova, Ciro; Esteban, Christobal; Soler-Cataluna, Juan J.; de Torres, Juan P.; Miravitlles, Marc; Celli, Bartolome R.; Tamm, Michael; Stolz, Daiana.

In: European respiratory journal, Vol. 47, No. 6, 2016, p. 1601-1605.

Research output: Contribution to journalArticleAcademic

TY - JOUR

T1 - Prognostic assessment in COPD without lung function: the B-AE-D indices

AU - Boeck, Lucas

AU - Soriano, Joan B.

AU - Brusse-Keizer, Marjolein

AU - Biasi, Francesco

AU - Kostikas, Konstantinos

AU - Boersma, Wim

AU - Milenkovic, Branislava

AU - Louis, Renaud

AU - Lacoma, Alicia

AU - Djamin, Remco

AU - Aerts, Joachim

AU - Torres, Antoni

AU - Rohde, Gernot

AU - Welte, Tobias

AU - Martinez-Camblor, Pablo

AU - Rakic, Janko

AU - Scherr, Andreas

AU - Koller, Michael

AU - van der Palen, Jacobus Adrianus Maria

AU - Gomez Marin, Jose M.

AU - Alfageme, Inmaculada

AU - Almagro, Pere

AU - Casanova, Ciro

AU - Esteban, Christobal

AU - Soler-Cataluna, Juan J.

AU - de Torres, Juan P.

AU - Miravitlles, Marc

AU - Celli, Bartolome R.

AU - Tamm, Michael

AU - Stolz, Daiana

PY - 2016

Y1 - 2016

N2 - Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function. The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988). Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C. It was observed that B-AE-D and B-AE-D-C were at least as good as BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity), ADO (age, dyspnoea, airflow obstruction) and DOSE (dyspnoea, obstruction, smoking, exacerbation) indices for predicting 2-year all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 0.63, respectively; Hosmer–Lemeshow test all p>0.05). Both indices were COPD specific (c-statistic for predicting COPD-related 2-year mortality: 0.87 and 0.89, respectively). External validation of B-AE-D was performed in COCOMICS and COMIC (c-statistic for 1-year all-cause mortality: 0.68 and 0.74; c-statistic for 2-year all-cause mortality: 0.65 and 0.67; Hosmer–Lemeshow test all p>0.05). The B-AE-D index, plus copeptin if available, allows a simple and accurate assessment of COPD-related risk

AB - Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function. The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988). Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C. It was observed that B-AE-D and B-AE-D-C were at least as good as BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity), ADO (age, dyspnoea, airflow obstruction) and DOSE (dyspnoea, obstruction, smoking, exacerbation) indices for predicting 2-year all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 0.63, respectively; Hosmer–Lemeshow test all p>0.05). Both indices were COPD specific (c-statistic for predicting COPD-related 2-year mortality: 0.87 and 0.89, respectively). External validation of B-AE-D was performed in COCOMICS and COMIC (c-statistic for 1-year all-cause mortality: 0.68 and 0.74; c-statistic for 2-year all-cause mortality: 0.65 and 0.67; Hosmer–Lemeshow test all p>0.05). The B-AE-D index, plus copeptin if available, allows a simple and accurate assessment of COPD-related risk

KW - IR-101435

KW - METIS-318027

U2 - 10.1183/13993003.01485-2015

DO - 10.1183/13993003.01485-2015

M3 - Article

VL - 47

SP - 1601

EP - 1605

JO - European respiratory journal

JF - European respiratory journal

SN - 0903-1936

IS - 6

ER -

Boeck L, Soriano JB, Brusse-Keizer M, Biasi F, Kostikas K, Boersma W et al. Prognostic assessment in COPD without lung function: the B-AE-D indices. European respiratory journal. 2016;47(6):1601-1605. https://doi.org/10.1183/13993003.01485-2015